Author

Mathieu Bernat

Observed name: M. Bernat

Institution: Basilea Pharmaceutica (Switzerland)

Observed institution: Basilea Pharmaceutica (Switzerland)

OpenAlex ID: A5108260060

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations

2024 · Andrea Necchi, Rodryg Ramlau, et al. · JNCI Cancer Spectrum · 10

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01

2026 · Mitesh J. Borad, Michele Droz dit Busset, et al. · Hepatology

Correlation between the infection of HPV virus and bladder cancer development

2018 · E.M. Borkowska, M. Bernat, et al. · European Urology Supplements

Works count: 3

Citation count: 10

H-index: 1

I10-index: 1